Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayato Nagasawa

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Clinical Calcium|March 3, 2009
[Effect of the inhibition of joint destruction in RA by TNF-blocking agents]Hayato Nagasawa, Tsutomu Takeuchi
Clinical and Experimental Rheumatology|June 8, 2010
Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical functionHayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, et al.
Modern Rheumatology|March 13, 2010
Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritisHayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, et al.
Modern Rheumatology|December 17, 2008
Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destructionHayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, et al.
Modern Rheumatology|November 21, 2013
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trialTakahiko Kurasawa, Hayato Nagasawa, Mayumi Kishimoto, et al.
Annals of the Rheumatic Diseases|October 29, 2010
Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritisAyumi Okuyama, Hayato Nagasawa, Katsuya Suzuki, et al.
Modern Rheumatology|January 7, 2014
Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patientsHideto Kameda, Koichi Amano, Naoya Sekiguchi, et al.
Plos One|May 26, 2012
Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapyYasuo Niki, Tsutomu Takeuchi, Masanori Nakayama, et al.
Internal Medicine (Tokyo, Japan)|November 17, 2009
Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseasesHideto Kameda, Koichi Amano, Hayato Nagasawa, et al.
Modern Rheumatology|April 18, 2007
Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritisHiroe Ogawa, Hideto Kameda, Hayato Nagasawa, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Clinical Calcium|March 3, 2009
[Effect of the inhibition of joint destruction in RA by TNF-blocking agents]Hayato Nagasawa, Tsutomu Takeuchi
Clinical and Experimental Rheumatology|June 8, 2010
Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical functionHayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, et al.
Modern Rheumatology|March 13, 2010
Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritisHayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, et al.
Modern Rheumatology|December 17, 2008
Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destructionHayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, et al.
Modern Rheumatology|November 21, 2013
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trialTakahiko Kurasawa, Hayato Nagasawa, Mayumi Kishimoto, et al.
Annals of the Rheumatic Diseases|October 29, 2010
Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritisAyumi Okuyama, Hayato Nagasawa, Katsuya Suzuki, et al.
Modern Rheumatology|January 7, 2014
Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patientsHideto Kameda, Koichi Amano, Naoya Sekiguchi, et al.
Plos One|May 26, 2012
Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapyYasuo Niki, Tsutomu Takeuchi, Masanori Nakayama, et al.
Internal Medicine (Tokyo, Japan)|November 17, 2009
Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseasesHideto Kameda, Koichi Amano, Hayato Nagasawa, et al.
Modern Rheumatology|April 18, 2007
Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritisHiroe Ogawa, Hideto Kameda, Hayato Nagasawa, et al.
Pageof 5